Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma

Sundar Jagannath; Meletios A Dimopoulos; Sagar Lonial

doi:10.1016/j.leukres.2010.04.001

Related publications

Article2013

The role of histone deacetylase inhibitors in patients with relapsed/refractory multiple myeloma

Roman Hájek, David S. Siegel, Robert Z. Orlowski, Heinz Ludwig, Antonio Palumbo, Meletios A Dimopoulos

Article2020

Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma

Meletios A Dimopoulos, Sara Galimberti, P. Anttila, Marcelo Capra, Michèle Cavo, Craig E. Cole, Cristina Gasparetto, Vânia Hungria, Matthew Jenner, Vladimir Vorobyev, Eduardo Yañez Ruiz, Jian Yin, Rao Saleem, Maeva Hellet, Sandrine Macé, Bruno Paiva, Ravi Vij

Article2015

Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma

Paul G. Richardson, Jacob P. Laubach, Sagar Lonial, Philippe Moreau, Sung‐Soo Yoon, Vânia TM Hungria, Meletios A Dimopoulos, Meral Beksaç, Melissa Alsina, Jesús F. San Miguel

Chapter in a book2017

Treatment of Relapsed/Refractory Patients with Multiple Myeloma

Jacob P. Laubach, Philippe Moreau, Meletios A Dimopoulos, Paul G. Richardson

Article2010

Vorinostat Combined with Bortezomib In Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Update on the Vantage Study Program

David S. Siegel, Sundar Jagannath, Roman Hájek, Meletios A Dimopoulos, Sung‐Soo Yoon, Sagar Lonial, Jacob P. Laubach, Thorsten Graef, Dina Pietrangelo, Lisa Lupinacci, David Reiser, Kenneth C. Anderson